Mouse Models of Breast Cancer in Preclinical Research

Overview

Journal Lab Anim Res

Date 2019 Jan 24

PMID 30671101

Citations 35

Authors

Mi Kyung Park

Chang Hoon Lee

Ho Lee

Affiliations

Soon will be listed here.

Abstract

Breast cancer remains the second leading cause of cancer death among woman, worldwide, despite advances in identifying novel targeted therapies and the development of treating strategies. Classification of clinical subtypes (ER+, PR+, HER2+, and TNBC (Triple-negative)) increases the complexity of breast cancers, which thus necessitates further investigation. Mouse models used in breast cancer research provide an essential approach to examine the mechanisms and genetic pathway in cancer progression and metastasis and to develop and evaluate clinical therapeutics. In this review, we summarize tumor transplantation models and genetically engineered mouse models (GEMMs) of breast cancer and their applications in the field of human breast cancer research and anti-cancer drug development. These models may help to improve the knowledge of underlying mechanisms and genetic pathways, as well as creating approaches for modeling clinical tumor subtypes, and developing innovative cancer therapy.

Citing Articles

Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.

Kaur R, Sharma A, Wijekoon N EXCLI J. 2025; 24:267-285.

PMID: 40071025 PMC: 11895054. DOI: 10.17179/excli2024-7973.

Mammary Cancer Models: An Overview from the Past to the Future.

Silva J, Oliveira P, Duarte J, Faustino-Rocha A In Vivo. 2024; 39(1):1-16.

PMID: 39740866 PMC: 11705154. DOI: 10.21873/invivo.13800.

Current Insights in Murine Models for Breast Cancer: Present, Past and Future.

Jain M, Goel A Curr Pharm Des. 2024; 30(29):2267-2275.

PMID: 38910416 DOI: 10.2174/0113816128306053240604074142.

A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer.

Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C Clin Exp Metastasis. 2024; 41(5):733-746.

PMID: 38717519 PMC: 11499368. DOI: 10.1007/s10585-024-10289-z.

Exploring the One Health Paradigm in Male Breast Cancer.

Tay K, Cowan G, Chatterji S, Conti G, Speirs V J Mammary Gland Biol Neoplasia. 2024; 29(1):8.

PMID: 38573417 PMC: 10995048. DOI: 10.1007/s10911-024-09560-6.

References

Cardiff R, Anver M, Gusterson B, Hennighausen L, Jensen R, Merino M . The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000; 19(8):968-88. DOI: 10.1038/sj.onc.1203277. View

Li Y, Hively W, Varmus H . Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000; 19(8):1002-9. DOI: 10.1038/sj.onc.1203273. View

Hoffman R . Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 2000; 17(4):343-59. DOI: 10.1023/a:1006326203858. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Renner M, Klein D, Muller M, Salmons B, Gunzburg W . The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Ther. 2002; 9(5):421-31. DOI: 10.1038/sj.cgt.7700456. View

Hwang T, Han H, Hong Y, Lee H, Paik N . Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int. 2003; 53(2):74-80. DOI: 10.1046/j.1440-1827.2003.01441.x. View

Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N . Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat. 2003; 79(2):241-52. DOI: 10.1023/a:1023956223037. View

Guy C, Cardiff R, Muller W . Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992; 12(3):954-61. PMC: 369527. DOI: 10.1128/mcb.12.3.954-961.1992. View

10.

Allred D, Clark G, Molina R, Tandon A, Schnitt S, Gilchrist K . Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23(9):974-9. DOI: 10.1016/0046-8177(92)90257-4. View

11.

Sutherland R, Musgrove E . Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004; 9(1):95-104. DOI: 10.1023/B:JOMG.0000023591.45568.77. View

12.

Aslakson C, Miller F . Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992; 52(6):1399-405. View

13.

Almholt K, Lund L, Rygaard J, Nielsen B, Dano K, Romer J . Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer. 2004; 113(4):525-32. DOI: 10.1002/ijc.20631. View

14.

Althuis M, Dozier J, Anderson W, Devesa S, Brinton L . Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005; 34(2):405-12. DOI: 10.1093/ije/dyh414. View

15.

Kuperwasser C, Dessain S, Bierbaum B, Garnet D, Sperandio K, Gauvin G . A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005; 65(14):6130-8. DOI: 10.1158/0008-5472.CAN-04-1408. View

16.

Herschkowitz J, Simin K, Weigman V, Mikaelian I, Usary J, Hu Z . Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76. PMC: 1929138. DOI: 10.1186/gb-2007-8-5-r76. View

17.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P . A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007; 13(13):3989-98. DOI: 10.1158/1078-0432.CCR-07-0078. View

18.

Hanahan D, Wagner E, Palmiter R . The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007; 21(18):2258-70. DOI: 10.1101/gad.1583307. View

19.

Jensen M, Schoepfer J, Radimerski T, Massey A, Guy C, Brueggen J . NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008; 10(2):R33. PMC: 2397535. DOI: 10.1186/bcr1996. View

20.

Tao K, Fang M, Alroy J, Sahagian G . Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008; 8:228. PMC: 2529338. DOI: 10.1186/1471-2407-8-228. View